Latest Patents

Patents imply intellectual property and it has a $ value that can be associated depending on the field and type of patent that is allocated. Patents also increase the enterprise value of the company and help prevent copy-cats from copying the idea without having royalt payments or licencing deals. We like it when companies get patents awarded!. To protect IP companies aggressively file provisional patents even before they have a working product. The below table provides a way to look at what has been done by companies and use this as a factor to make investment decisions.

     
Title Filing Date Publication Date Grant Date
Methods of manufacturing treprostinil and treprostinil derivative prodrugs 2023-4-18 2023-8-10
Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating … 2023-2-16 2023-8-24
Dry powder compositions of bedaquiline and salts and methods of use thereof 2023-2-06 2023-8-10
Methods for continuous manufacture of liposomal drug products 2022-12-30 2023-7-13
Lipid-based compositions of antiinfectives for treating pulmonary infections … 2022-12-22 2023-5-04
Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating … 2022-10-28 2023-5-04
Methods for treating pulmonary non-tuberculous mycobacterial infections 2022-10-07 2023-2-09
Sustained release of antiinfectives 2022-9-09 2023-1-12
Dry powder compositions of treprostinil prodrugs and methods of use thereof 2022-8-23 2022-12-29
Tunable polymeric nanoparticles for targeted and sustained delivery of … 2022-8-19 2023-2-23
Adeno-associated virus particles and methods of use thereof 2022-8-05 2023-2-09
In vitro release assay methods for liposomal aminoglycoside formulations 2022-6-08 2022-12-15
Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating … 2022-4-29 2022-11-03
Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating … 2022-4-28 2022-11-03
Combination therapy for treating non-tuberculous mycobacterial lung disease 2022-3-24 2022-9-29
Dry powder compositions of glycopeptide derivative compounds and methods of use … 2022-3-18 2022-9-22
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for … 2022-1-14 2022-5-05
Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides … 2021-12-22 2022-6-30
Dry powder compositions of treprostinil prodrugs and methods of use thereof 2021-10-28 2022-5-05
Methods for treating newly diagnosed mycobacterium avium complex lung … 2021-8-30 2023-3-02
Methods for extracting neutrophil serine proteases and treating dipeptidyl … 2021-7-19 2023-5-24
Lipo-glycopeptide cleavable derivatives and uses thereof 2021-6-10 2022-5-05
Pharmaceutical formulations of treprostinil prodrugs and methods of use thereof 2021-3-25 2023-2-08
Deimmunized lysostaphin and methods of use 2021-3-12 2021-12-23
Sustained release of antiinfectives 2021-3-10 2022-1-20
Prostacyclin compounds 2021-3-02 2021-4-30
Systems for treating pulmonary infections 2021-2-12 2021-12-02
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for … 2021-1-25 2021-6-24
Sustained release of antiinfectives 2020-10-30 2021-4-29
Methods for treating pulmonary non-tuberculous mycobacterial infections 2020-9-22 2020-12-11
Compositions and methods for treating lung diseases and lung injury 2020-5-22 2020-6-11
Lipo-glycopeptide cleavable derivatives and uses thereof 2019-11-20 2021-9-29
Glycopeptide derivative compounds and uses thereof 2019-11-20 2021-9-29
Specific (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamide for … 2019-7-16 2021-3-24
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for … 2019-7-16 2020-1-23
Methods for the manufacture of liposomal drug formulations 2019-5-02 2019-11-07
Stabilized vancomycin formulations 2018-9-26 2019-11-12 2019-11-12
Compositions of multicationic drugs for reducing interactions with polyanionic … 2018-2-12 2018-6-21
Methods of treating pulmonary disorders with liposomal amikacin formulations 2017-6-30 2017-12-21
Prostacyclin compounds and compositions for treating sarcoidosis 2017-6-23 2017-12-28
Antibodies and methods of making same 2017-5-24 2023-5-16 2023-5-16
Methods of treating pulmonary disorders with liposomal amikacin formulations 2017-4-27 2017-6-29
Compositions and methods for treating bacterial infections 2016-11-18 2017-6-15
High delivery rates for lipid based drug formulations, and methods of treatment … 2016-9-27 2017-1-19
Compositions comprising copper chelators and methods of use thereof for … 2016-7-28 2017-2-02
Compositions and methods for the treatment of sarcoidosis 2016-7-25 2017-2-02
Prostacyclin compounds, compositions and methods of use thereof 2016-4-29 2016-11-03
Prostacylin compositions and methods for using the same 2016-4-07 2016-10-07
Platinum aggregates and process for producing the same 2015-10-12 2016-9-15
Methods of treating cancer with high potency lipid-based platinum compound … 2015-7-10 2016-6-16
LONG-TERM RELEASE OF ANTI-COLLAPSE MEDICINES 2015-6-17 2017-2-08
Prostacylin compositions and methods for using the same 2015-3-10 2015-9-17
Prostacyclin compounds, compositions and methods of use thereof 2014-10-24 2021-6-29
Prostacyclin compounds, compositions and methods of use thereof 2014-10-24 2021-3-26
Prostacyclin compounds, compositions and methods of use thereof 2014-10-24 2021-6-29
Prostacyclin compounds, compositions and methods of use thereof 2014-10-24 2016-5-12
Low resistance aerosol exhalation filter 2014-7-17 2018-11-08 2018-11-08
Liposomal vancomycin formulations 2014-5-20 2016-11-24 2016-11-24
Methods of treating pulmonary disorders with liposomal amikacin formulations 2014-3-25 2014-4-17
Method for treating pulmonary disorders with liposomal amikacin formulations 2012-8-03 2016-5-10 2016-5-10
Methods for coacervation induced liposomal encapsulation and formulations … 2007-4-04 2018-2-21 2018-2-21
Purified rhIGF-I/rhIGFBP-3 complexes and their method of manufacture 2005-12-20 2011-6-28 2011-6-28
Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents 2003-12-18 2004-7-22
Methods for the production of D-chiro-inositol and the use of D-chiro-inositol … 2002-11-08 2005-8-26
Compositions and methods for preventing neural tube disorders 2002-6-05 2002-12-12
Compositions comprising D-chiro inositol and lipid lowering compounds 2002-5-17 2006-2-11 2006-2-11
Compositions comprising d-chiro inositol and lipid lowering compounds and … 2002-5-15 2002-12-03
Compositions comprising d-chiro inositol and sulfonylureas and methods of … 2002-5-01 2003-4-24
Compositions containing hypotriglyceridemically active stilbenoids 2001-8-16 2002-2-21
Compositions containing hypotriglyceridemically active stilbenoids 2001-8-15 2003-5-21
Compositions containing hypoglycemically active stilbenoids 2001-8-15 2005-4-27 2005-4-27
Compositions containing hypoglycemically active stilbenoids 2001-8-15 2002-9-12